Want to join the conversation?
$AMGN said FDA approved Amjevita (adalimumab-atto) for the treatment of seven inflammatory diseases. This includes moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic plaque psoriasis, Crohn's disease and ulcerative colitis.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.